Search Results - "Dotsu, Yosuke"

Regression of a Non-Irradiated Lung Adenocarcinoma During Glioblastoma-Directed Chemoradiotherapy: A Case Report.

Authors: Iwanaga, Mizuki Dotsu, Yosuke Hiu, Takeshi et al.

Source: Current Oncology. Apr2026, Vol. 33 Issue 4, p188. 10p.

Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies.

Authors: Sen, Triparna Dotsu, Yosuke Corbett, Virginia et al.

Source: Lancet Oncology. Jan2025, Vol. 26 Issue 1, pe13-e33. 21p.

Dabrafenib and trametinib therapy in an elderly patient with non‐small cell lung cancer harboring the BRAF V600E mutation.

Authors: Dotsu, Yosuke Fukuda, Minoru Honda, Noritaka et al.

Source: Thoracic Cancer. Jan2021, Vol. 12 Issue 2, p272-276. 5p.

Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor.

Authors: Dotsu, Yosuke Yamaguchi, Hiroyuki Fukuda, Minoru et al.

Source: Journal of Clinical Medicine. Sep2021, Vol. 10 Issue 18, p4221. 1p.

Hypertrophic osteoarthropathy associated with lung cancer: Possible links among hypoxia‐inducible factor‐1α, vascular endothelial growth factor, and hypervascularization.

Authors: Tagawa, Ryuta Soda, Hiroshi Dotsu, Yosuke et al.

Source: Thoracic Cancer. May2023, Vol. 14 Issue 14, p1320-1324. 5p.

Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer.

Authors: Taniguchi, Hirokazu Yamaguchi, Hiroyuki Dotsu, Yosuke et al.

Source: Thoracic Cancer. Sep2019, Vol. 10 Issue 9, p1764-1769. 6p.

Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma.

Authors: Ikeda, Takaya Yamaguchi, Hiroyuki Dotsu, Yosuke et al.

Source: Thoracic Cancer. Nov2018, Vol. 9 Issue 11, p1522-1524. 3p.

Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study.

Authors: Tomono, Hiromi Taniguchi, Hirokazu Fukuda, Minoru et al.

Source: Thoracic Cancer. Oct2023, Vol. 14 Issue 28, p2890-2894. 5p.

Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases.

Authors: Ogata, Ryosuke Soda, Hiroshi Senju, Hiroaki et al.

Source: Thoracic Cancer. Oct2022, Vol. 13 Issue 19, p2812-2816. 5p.

Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited‐disease small cell lung cancer: protocol of ACIST study.

Authors: Akagi, Kazumasa Taniguchi, Hirokazu Fukuda, Minoru et al.

Source: Thoracic Cancer. Aug2022, Vol. 13 Issue 16, p2404-2409. 6p.

Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody.

Authors: Saiki, Masafumi Yoshizawa, Takahiro Dotsu, Yosuke et al.

Source: Lung Cancer (01695002). Jul2019, Vol. 133, p4-9. 6p.

Efficacy of S‐1 after pemetrexed in patients with non‐small cell lung cancer: A retrospective multi‐institutional analysis.

Authors: Takemoto, Shinnosuke Akagi, Kazumasa Ono, Sawana et al.

Source: Thoracic Cancer. Sep2021, Vol. 12 Issue 17, p2300-2306. 7p.

Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report.

Authors: Taniguchi, Hirokazu Takemoto, Shinnosuke Ozasa, Mutsumi et al.

Source: Thoracic Cancer. Apr2021, Vol. 12 Issue 7, p1126-1130. 5p.

Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study.

Authors: Ikeda, Takaya Takemoto, Shinnosuke Senju, Hiroaki et al.

Source: Thoracic Cancer. Jul2020, Vol. 11 Issue 7, p1972-1978. 7p.

Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small cell lung cancer.

Authors: Akagi, Kazumasa Taniguchi, Hirokazu Fukuda, Minoru et al.

Source: Lung Cancer (01695002). Apr2026, Vol. 214, pN.PAG-N.PAG. 1p.

Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study.

Authors: Takemoto, Shinnosuke Fukuda, Minoru Yamaguchi, Hiroyuki et al.

Source: Thoracic Cancer. Feb2020, Vol. 11 Issue 2, p389-393. 5p.

Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer.

Authors: Shimada, Midori Yamaguchi, Hiroyuki Fukuda, Minoru et al.

Source: Cancer Chemotherapy & Pharmacology. Nov2019, Vol. 84 Issue 5, p1059-1064. 6p.

Acute amivantamab-induced myocardial injury in a patient with epidermal growth factor receptor-mutant lung cancer: a first case report.

Authors: Kaneko S Dotsu Y Inoue T et al.

Source: Frontiers in oncology [Front Oncol] 2025 Dec 09; Vol. 15, pp. 1708575. Date of Electronic Publication: 2025 Dec 09 (Print Publication: 2025).

Publication Type: Case Reports; Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

Targeting heterogeneity in atypical epidermal growth factor receptor-mutated non-small cell lung cancer: insights from CHRYSALIS-2.

Authors: Dotsu Y Mukae H

Source: Translational lung cancer research [Transl Lung Cancer Res] 2026 May 31; Vol. 15 (5), pp. 116. Date of Electronic Publication: 2026 May 26.

Publication Type: Editorial; Comment

Journal Info: Publisher: Pioneer Bioscience Publishing Company Country of Publication: China NLM ID: 101646875 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2218-6751 (Print) Linking ISSN: 22186751 NLM ISO Abbreviation: Transl Lung Cancer Res Subsets: PubMed not MEDLINE

Genomic landscape of pleural mesothelioma in Japanese patients: A comprehensive analysis using nationwide database.

Authors: Taniguchi H Akagi K Fukuda T et al.

Source: Translational oncology [Transl Oncol] 2026 May; Vol. 67, pp. 102731. Date of Electronic Publication: 2026 Mar 18.

Publication Type: Journal Article

Journal Info: Publisher: Neoplasia Press Country of Publication: United States NLM ID: 101472619 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1936-5233 (Print) Linking ISSN: 19365233 NLM ISO Abbreviation: Transl Oncol Subsets: PubMed not MEDLINE